121 related articles for article (PubMed ID: 11857384)
1. Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer.
Suzuki N; Maeda Y; Tanaka S; Hida N; Mine T; Yamamoto K; Oka M; Itoh K
Int J Cancer; 2002 Mar; 98(1):45-50. PubMed ID: 11857384
[TBL] [Abstract][Full Text] [Related]
2. Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients.
Maeda Y; Hida N; Niiya F; Katagiri K; Harada M; Yamana H; Kamura T; Takahashi M; Sato Y; Todo S; Itoh K
Br J Cancer; 2002 Sep; 87(7):796-804. PubMed ID: 12232766
[TBL] [Abstract][Full Text] [Related]
3. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
4. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation.
Hida N; Maeda Y; Katagiri K; Takasu H; Harada M; Itoh K
Cancer Immunol Immunother; 2002 Jun; 51(4):219-28. PubMed ID: 12012109
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
[TBL] [Abstract][Full Text] [Related]
6. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
[TBL] [Abstract][Full Text] [Related]
7. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
8. Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients.
Niu Y; Terasaki Y; Komatsu N; Noguchi M; Shichijo S; Itoh K
Cancer Sci; 2009 Nov; 100(11):2167-74. PubMed ID: 19689476
[TBL] [Abstract][Full Text] [Related]
9. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
11. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
[TBL] [Abstract][Full Text] [Related]
12. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery.
Tanaka S; Harada M; Mine T; Noguchi M; Gohara R; Azuma K; Tamura M; Yamada A; Morinaga A; Nishikori M; Katagiri K; Itoh K; Yamana H; Hashimoto T
J Immunother; 2003; 26(4):357-66. PubMed ID: 12843798
[TBL] [Abstract][Full Text] [Related]
13. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
15. Expression of the SART3 antigens in oral cancers.
Fukuda K
Kurume Med J; 2001; 48(1):55-8. PubMed ID: 11402621
[TBL] [Abstract][Full Text] [Related]
16. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.
Harada M; Ishihara Y; Itoh K; Yamanaka R
Oncol Rep; 2007 Mar; 17(3):629-36. PubMed ID: 17273744
[TBL] [Abstract][Full Text] [Related]
17. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.
Harashima N; Tanaka K; Sasatomi T; Shimizu K; Miyagi Y; Yamada A; Tamura M; Yamana H; Itoh K; Shichijo S
Eur J Immunol; 2001 Feb; 31(2):323-32. PubMed ID: 11180095
[TBL] [Abstract][Full Text] [Related]
18. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
20. Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer-associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome.
Maeda A; Ohguro H; Nabeta Y; Hirohashi Y; Sahara H; Maeda T; Wada Y; Sato T; Yun C; Nishimura Y; Torigoe T; Kuroki Y; Sato N
Eur J Immunol; 2001 Feb; 31(2):563-72. PubMed ID: 11180121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
